Aventis Pharma today said its net profit declined by 20.75% to Rs 40.1 crore for the first quarter ended March 31, 2012, over the same period previous year.
The pharmaceutical company reported a net profit of Rs 50.6 crore in the same period of previous year, Aventis Pharma said in a BSE filing.
"The profit of the quarter has been impacted due to the amortisation costs relating to the brands and technical know how acquired in 2011 from Universal Medicare and lower interest income as a result of the above investment," it said.
Net sales of the company rose to Rs 322.5 crore for the first quarter ended March 31, 2012, as compared to Rs 276.3 crore in the corresponding period of last year.
The company's board, which met today, recommended a final dividend of Rs 29 per share of a face value of Rs 10 for the year ended December 31, 2012.
Shares of the company today closed at Rs 2,138.10 on the BSE, down 2.67% over its previous close.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
